Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1349042 | 1.00 | CYP3A4 (0.38) | CYP3A4TRPV1 | |
| SCHEMBL1350078 | 0.79 | CYP3A4 (0.57) | CYP3A4TRPV1 | |
| SCHEMBL1348834 | 0.79 | CYP3A4 (0.57) | CYP3A4TRPV1 | |
| SCHEMBL2127579 | 0.79 | CYP3A4 (0.64) | CYP3A4TRPV1 | |
| SCHEMBL1542551 | 0.79 | CYP3A4 (0.64) | CYP3A4TRPV1 | |
| SCHEMBL8219660 | 0.74 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL2127641 | 0.71 | CYP3A4 (0.65) | CYP3A4TRPV1 | |
| SCHEMBL2127645 | 0.71 | CYP3A4 (0.65) | CYP3A4TRPV1 | |
| SCHEMBL1543266 | 0.71 | CYP3A4 (0.65) | CYP3A4TRPV1 | |
| SCHEMBL1542773 | 0.68 | CYP3A4 (0.68) | CYP3A4TRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063072-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2011-11-22 | — | — | US | disclosed |
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | LI JIM | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070189-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, HCCS, RTF2 | CYP3A4 305/4885TRPV1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.